Advertisement
UK markets closed
  • FTSE 100

    7,820.36
    -145.17 (-1.82%)
     
  • FTSE 250

    19,344.54
    -354.35 (-1.80%)
     
  • AIM

    738.28
    -12.00 (-1.60%)
     
  • GBP/EUR

    1.1699
    -0.0012 (-0.10%)
     
  • GBP/USD

    1.2429
    -0.0017 (-0.14%)
     
  • Bitcoin GBP

    49,759.70
    -2,432.31 (-4.66%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,053.21
    -8.61 (-0.17%)
     
  • DOW

    37,841.13
    +106.02 (+0.28%)
     
  • CRUDE OIL

    85.49
    +0.08 (+0.09%)
     
  • GOLD FUTURES

    2,404.10
    +21.10 (+0.89%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     
  • DAX

    17,766.23
    -260.35 (-1.44%)
     
  • CAC 40

    7,932.61
    -112.50 (-1.40%)
     

Boston Scientific’s Rhythm Management & Neuro Segment

Boston Scientific’s Rhythm Management & Neuro Segment

Revenues from Boston Scientific’s (BSX) urology and pelvic health area increased from $262 million in Q1 2017 to $293 million in Q1 2018. Its US revenues increased from $183 million in Q1 2017 to $197 million in Q1 2018.